BioCryst to Present at 2021 Cantor Virtual Healthcare Conference

BioCryst Pharmaceuticals (Nasdaq: BCRX) will present at the 2021 Cantor Virtual Healthcare Conference on September 28, 2021, at 2:00 p.m. ET.

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) will present at the 2021 Cantor Virtual Healthcare Conference on September 28, 2021, at 2:00 p.m. ET. Investors can access the live audio webcast and replay on the company's website. BioCryst specializes in developing novel oral medicines for rare diseases, with approved products such as ORLADEYO® for certain medical conditions. The company is also working on several other treatments, including BCX9930 for complement-mediated diseases and galidesivir for viral infections.

Argus Session date unavailable

+2.00% session move Open Argus

Details

News Market Reaction – BCRX

The recorded move for BCRX in the trading session of this news was +2.00%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 2021 Cantor Virtual Healthcare Conference on Tuesday, September 28, 2021 at 2:00 p.m. ET.

Links to a live audio webcast and replay of this presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States, the European Union, Japan, the United Kingdom and the United Arab Emirates. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investors:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is BioCryst Pharmaceuticals presenting at the Cantor Virtual Healthcare Conference?

BioCryst Pharmaceuticals will present on September 28, 2021, at 2:00 p.m. ET.

How can I access the BioCryst Pharmaceuticals conference presentation?

You can access the live audio webcast and replay of the presentation on BioCryst's Investors section of their website.

What is ORLADEYO® and where is it approved?

ORLADEYO® (berotralstat) is an oral treatment approved in the U.S., EU, Japan, UK, and UAE for rare diseases.

What ongoing development programs does BioCryst have?

BioCryst has ongoing programs for BCX9930, BCX9250, and galidesivir, targeting various diseases and conditions.

What regulatory approvals has RAPIVAB® received?

RAPIVAB® (peramivir injection) has been approved in the U.S., Canada, Australia, Japan, Taiwan, and Korea.